Renee Maria Saliby (@ReneeSaliby) ranks #33 among US lung cancer KOLs, #23 among US gu cancer KOLs on X in 2026, by engagement from fellow physicians. 25 physicians shared, quoted or replied to their posts this year. Most-discussed trials in 2026: LITESPARK-022, LITESPARK-011.
At a Glance
- 2 posts naming a trial in 2026
- 2 trials discussed by name
- Lung Cancer: US #33 · 7 physicians engaged
- GU Cancer: US #23 · 25 physicians engaged
This Month
What Renee Maria Saliby has posted in the last 30 days. Updated November 10, 2026.
No trial posts in the last 30 days.
Who Amplifies Renee Maria Saliby
Physicians who reposted Renee Maria Saliby’s trial posts most often in 2026.
2026 Rankings
| List | US rank | Global rank | Physicians engaged | Physician engagements | |
|---|---|---|---|---|---|
| Lung Cancer | #33 | — | 7 | 7 | Full ranking |
| GU Cancer | #23 | — | 25 | 27 |
What Colleagues Are Saying About Renee Maria Saliby
2026 posts by fellow physicians that mention @ReneeSaliby, quoted word for word.
Heme/onc fellowship applicant @reneesaliby looks at mechanisms of resistance to nivolumab in older adults with mRCC. Individualized targeting of these pathways could help overcome resistance. @YaleIMed @DanaFarber @myESMO #ESMO26 @OncoAlert @DanaFarber_GU https://t.co/AP3HQrbMRj
Trials Renee Maria Saliby Discussed in 2026
| Trial | Posts | Rank among physicians posting | Latest |
|---|---|---|---|
| LITESPARK-022 | 1 | #21 of 40 | Feb 28, 2026 |
| LITESPARK-011 | 1 | #16 of 37 | Feb 28, 2026 |
Renee Maria Saliby on LITESPARK-022
🚨LITESPARK-022: Largest study in adjuvant therapy evaluating IO @DrChoueiri changing the landscape of RCC (at every stage of disease) year after year: this year #GU26 pembro/bel improves DFS compared to bel ⭐️ OS to follow! @DanaFarber @OncoAlert https://t.co/OTD7qQZc3F
Renee Maria Saliby on LITESPARK-011
LITESPARK-011 shows improved PFS with belzutifan/lenv vs cabo in pts with mRCC having after PD(L)1 Amazing presentation by @motzermd in what has been a difficult space for pts and physicians Improved ORR as well as DOR! Pending final OS analysis... @OncoAlert #GU26 https://t.co/Jmg5kKZXIb
Renee Maria Saliby’s Most-Engaged Posts in 2026
Their own 2026 posts that fellow physicians reposted most, quoted word for word.
✨✨Hope alert: @sands_jacob shows that adding tarla to durva for maintenance therapy significantly improves survival to 21.1mo! Followed by a masterful discussion by @StephenVLiu integrating clinical outcomes including tox, translational thoughts, and accessibility! "We cannot allow the inequities in the delivery of our care be our legacy" #ESMO26 @OncoAlert
Leveraging ENPP3 expression on RCC - @montypal presents the results of the ph I trial of ENPP3 x CD3 bispecific Cytokine-related adverse events occur mostly in early cycles Super promising antitumor activity with signs of durability so far #ESMO26 @OncoAlert https://t.co/lRDXz4btwY
Rigorous biomarker trials are extremely difficult to design. @AlbigesL is doing it! Looking forward to seeing the results at a future meeting. #ESMO26 @OncoAlert https://t.co/2Gs9AjrUjf
A little history recap: 2021: KN564 is positive 2024: KN564 shows the first OS improvement in adjuvant therapy in ANY type of cancer 2026: let's do better than KN564, pembro/bel > pembro @DrChoueiri
Cabo has been the preferred 2nd line therapy for many years in mRCC Today, @DrDanielHeng shows that Bel + Len can offer improved significantly PFS and ORR! #ESMO26 @OncoAlert https://t.co/MqbDEPnavQ